Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LG Life Sciences Expands Diabetes Drug Market To 104 Countries

This article was originally published in PharmAsia News

Executive Summary

LG Life Sciences has reached an outlicensing deal with Mexico's Stendhal to market the Zemiglo (gemigliptin) and ZemiMet diabetes drugs in 23 Central and South America countries.

You may also be interested in...



Getting Its ACT Together: EXACT-Tx Raises NOK155m

EXACT-Tx will use funds from a NOK155m private placing to harness ultrasound in precision therapeutic targeting across a variety of indications and product classes.

Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s

More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.

QUOTED. 14 July 2020. Stephen Furlong.

With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. The first of a two-part series on mental health focuses on transcranial magnetic stimulation systems. See what Neuronetics’ CEO Stephen Furlong said about it here.

Topics

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel